The injectable medroxyprogesterone acetate suspension brought in $211 million in sales this year in the U.S., according to the Jerusalem-based pharma giant.
“This reintroduction brings an additional product to a market that was previously lacking in options,” Hafrun Fridriksdottir, EVP & president of Teva’s global generics R&D, said in prepared remarks. “In addition to its importance to patients who will benefit from access to this medicine, this reintroduction holds significant importance to Teva and our generics R&D priorities.”
The move comes just a few days after Teva said it planned to sell off its global women’s health business in a $2.48 billion deal. The company plans to use the funds to repay term loan debt.
CVC Capital Partners Fund VI is set to acquire a portfolio of products including Teva’s Ovaleap, Zoely, Seasonique, Colpotrophine, Actonel and others, for $703 million in cash.
Teva also inked an agreement with Foundation Consumer Healthcare for $675 million in cash. According to that deal, Foundation Consumer Healthcare will acquire Teva’s Plan B One-Step and its brands of emergency contraception, including Take Action and Next Choice One Dose.
The transactions are expected to close by the end of the year.
The pharmaceutical company plans to divest of its oncology and pain businesses in Europe, narrowing its focus on CNS and respiratory conditions as its therapeutic areas of focus.